EA200501252A1 - Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты) - Google Patents

Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты)

Info

Publication number
EA200501252A1
EA200501252A1 EA200501252A EA200501252A EA200501252A1 EA 200501252 A1 EA200501252 A1 EA 200501252A1 EA 200501252 A EA200501252 A EA 200501252A EA 200501252 A EA200501252 A EA 200501252A EA 200501252 A1 EA200501252 A1 EA 200501252A1
Authority
EA
Eurasian Patent Office
Prior art keywords
preparation
medication
options
basis
liposomal composition
Prior art date
Application number
EA200501252A
Other languages
English (en)
Inventor
Имран Ахмад
Гопал Аньярамбхатла
Лань Ма
Сидней Угву
Цзя-Ай Чжанг
Original Assignee
Неофарм, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Неофарм, Инк. filed Critical Неофарм, Инк.
Publication of EA200501252A1 publication Critical patent/EA200501252A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение представляет собой препарат одного или более противоопухолевых лекарственных веществ, инкапсулированных в липосомах, включающих в дополнение к противоопухолевому лекарственному препарату, по меньшей мере, липидную фракцию, причем композиция стабильна в водном растворе при комнатной температуре.Отчет о международном поиске был опубликован 2004.11.11.
EA200501252A 2003-02-03 2004-02-03 Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты) EA200501252A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44495803P 2003-02-03 2003-02-03
PCT/US2004/003157 WO2004069224A2 (en) 2003-02-03 2004-02-03 Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs

Publications (1)

Publication Number Publication Date
EA200501252A1 true EA200501252A1 (ru) 2006-02-24

Family

ID=32850955

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501252A EA200501252A1 (ru) 2003-02-03 2004-02-03 Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты)

Country Status (9)

Country Link
US (1) US8298573B2 (ru)
EP (1) EP1596825A2 (ru)
JP (1) JP4711947B2 (ru)
KR (1) KR20050105451A (ru)
CN (1) CN1700906A (ru)
BR (1) BRPI0407096A (ru)
EA (1) EA200501252A1 (ru)
MX (1) MXPA05008284A (ru)
WO (1) WO2004069224A2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
WO2007139930A2 (en) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
PT2271348T (pt) * 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
EP2394640A1 (en) * 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
ES2863659T3 (es) * 2016-01-07 2021-10-11 Univ Western Health Sciences Formulaciones para el tratamiento del cáncer de vejiga
SG11201903326RA (en) * 2016-10-28 2019-05-30 Servier Lab Liposomal formulation for use in the treatment of cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419348A (en) 1981-04-27 1983-12-06 Georgetown University Anthracycline glycoside compositions, their use and preparation
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5041278A (en) * 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US4898735A (en) * 1985-12-06 1990-02-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Liposome/doxorubicin composition and method
US4812314A (en) 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
EP0331504B1 (en) * 1988-03-04 1992-06-10 Takeda Chemical Industries, Ltd. Liposome composition
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
ATE194767T1 (de) * 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
JPH06329533A (ja) 1993-05-20 1994-11-29 Kyowa Hakko Kogyo Co Ltd リポソーム製剤の製造法
US5554382A (en) * 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
JP3431222B2 (ja) * 1993-08-20 2003-07-28 ティーディーケイ株式会社 磁気記録媒体の製造方法
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
KR970701551A (ko) 1994-03-11 1997-04-12 고야 마사시 리포좀 제제(liposome preparation)
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5696153A (en) * 1994-05-16 1997-12-09 Napro Biotherapeutics, Inc. Therapeutic regimen for treating patients
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US6066331A (en) * 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
DE4447770C2 (de) * 1994-08-20 2002-12-19 Max Delbrueck Centrum Verfahren zur Herstellung von liposomal verkapseltem Taxol
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
DE69528077T2 (de) 1994-11-18 2003-04-17 Aphios Corp Verfahren zur Herstellung von Liposomen, die hydrophobische Artzneistoffe enthalten
US5580899A (en) 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5693336A (en) * 1995-06-07 1997-12-02 Nexstar Pharmaceuticals, Inc. Blood stable liposomal cyclosporin formulations
US5703117A (en) 1995-09-12 1997-12-30 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
CA2250295C (en) 1996-03-12 2008-12-30 Pg-Txl Company L.P. Water soluble paclitaxel prodrugs
US5756537A (en) * 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
BRPI9810945B8 (pt) 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
NZ525552A (en) * 2000-11-09 2005-04-29 Neopharm Inc SN-38 lipid complexes with cardiolipin and methods of use for the treatment of cancers and multiple sclerosis
WO2003000190A2 (en) * 2001-06-25 2003-01-03 Depuy Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints

Also Published As

Publication number Publication date
KR20050105451A (ko) 2005-11-04
WO2004069224A3 (en) 2004-11-11
JP4711947B2 (ja) 2011-06-29
CN1700906A (zh) 2005-11-23
MXPA05008284A (es) 2006-03-21
WO2004069224A2 (en) 2004-08-19
JP2006516650A (ja) 2006-07-06
US20060029658A1 (en) 2006-02-09
BRPI0407096A (pt) 2006-01-24
US8298573B2 (en) 2012-10-30
EP1596825A2 (en) 2005-11-23

Similar Documents

Publication Publication Date Title
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
EA200400777A1 (ru) Фармацевтические композиции соединения платины
BR0207726A (pt) Sais farmacêuticos
CY1110558T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
BRPI0608297A2 (pt) composições de lipossomos
BR0210139A (pt) Composições farmacêuticas
BR0214469A (pt) 17alfa-alquil-17beta-óxi-estratrienos e produtos intermediários para sua preparação, aplicação dos 17alfa-alquil-17beta-óxi-estratrienos para a preparação de medicamentos bem como preparações farmacêuticas
FR11C0017I2 (fr) Utilisation de spinosad ou d'une formulation comprennant spinosad
BR0208338A (pt) Derivados de piridina
EP2316418A3 (en) Transmucosal drug delivery system
CA2439500A1 (en) Drug delivery system for hydrophobic drugs
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
CY1107672T1 (el) Φαρμακευτικες και/ή κοσμητικες συνθεσεις για τη θεραπεια εντοπισμενου αδιπικου ιστου και κυτταριτιδας
EA200602092A1 (ru) Способ и композиция для лечения ринита
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
DE60210552D1 (de) Prozess zur Herstellung einer festen pharmazeutischen Zubereitung welche einen schwerlöslichen Wirkstoff enthält
EA199900715A1 (ru) Липидные комплексы и липосомы совершенно нерастворимых комплексов платины
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
WO2000003753A3 (en) Microdisperse drug delivery systems
EA200501252A1 (ru) Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты)
WO2004017943A3 (en) Non-vesicular cationic lipid formulations
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες